anastrozole

Known as: Anastrozol, 1,3-Benzenediacetonitrile, alpha,alpha,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, anastrozole [Chemical/Ingredient] 
A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure. As a third-generation aromatase inhibitor… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
BACKGROUND The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin… (More)
  • table 1
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Little data exist on whether efficacy benefits or side-effects persist after 5 years of adjuvant treatment with an… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Previous research evaluating adherence to tamoxifen therapy among women with early-stage breast cancer has revealed… (More)
  • figure 1
  • figure 3
  • table 1
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial (median follow-up, 68 months) has shown that adjuvant… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Tamoxifen has been the standard adjuvant treatment for postmenopausal women with hormone-responsive early breast… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Tamoxifen, which is actually the gold standard adjuvant treatment in estrogen receptor-positive early breast cancer, is… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND In the adjuvant setting, tamoxifen is the established treatment for postmenopausal women with hormone-sensitive breast… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?